The global Urinary Tract Infection Testing Market is witnessing steady growth as the prevalence of urinary tract infections increases across different age groups. Rising awareness of early disease detection, growing demand for accurate diagnostic solutions, and advancements in molecular testing technologies are transforming the clinical diagnostics landscape. Healthcare providers are increasingly adopting rapid diagnostic tests, automated urine analyzers, and point-of-care testing solutions to improve diagnostic efficiency and patient outcomes. Additionally, the growing geriatric population, increasing incidence of recurrent UTIs, and concerns regarding antimicrobial resistance are encouraging investments in advanced testing technologies. The expansion of home-based testing solutions and digital healthcare services is also creating new opportunities for market participants.

Download a free sample copy of the Urinary Tract Infection Testing market report to understand detailed coverage and inclusions in the final report

Market Size and Growth Projections

The global urinary tract infection testing market was valued at USD 688.4 million in 2025 and is estimated to reach USD 726.1 million in 2026. According to Grand View Research, the market is projected to reach USD 1.1 billion by 2033, registering a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.

Key Market Statistics

• 2025 market size: USD 688.4 million
• 2026 estimated market size: USD 726.1 million
• 2033 projected market size: USD 1.1 billion
• Market CAGR: 5.5% from 2026 to 2033
• Largest region: North America, accounting for approximately 35.0% of global revenue in 2025
• Largest type segment: Cystitis, with more than 40.0% revenue share in 2025
• Largest end-use segment: Reference laboratories, with more than 25.0% revenue share in 2025
• Fastest-growing region: Asia Pacific

The increasing need for reliable diagnostic testing, combined with rising healthcare expenditure and improved access to laboratory services, is expected to support market expansion through 2033.

Key Trends and Market Drivers

The rising prevalence of urinary tract infections is a major factor driving demand for diagnostic testing. UTIs can affect different parts of the urinary system, including the urethra, bladder, and kidneys. Early diagnosis helps healthcare professionals identify infections, determine their severity, and select appropriate treatment. Women experience a higher incidence of UTIs, while older adults and patients with diabetes or other underlying conditions may face increased infection risks.

Growing concerns about antimicrobial resistance (AMR) are also encouraging the adoption of advanced testing solutions. Conventional diagnostic methods may require time to identify bacterial growth and determine antibiotic susceptibility. Molecular diagnostics and antimicrobial resistance testing can provide additional information to support treatment decisions and antimicrobial stewardship.

Another important growth driver is the increasing demand for rapid and point-of-care testing. Portable diagnostic devices, urine dipstick tests, and automated analyzers can support faster preliminary assessment in hospitals, clinics, and urgent care settings. At-home urine sample collection and self-testing solutions are also improving convenience for individuals experiencing recurrent infections.

However, false-positive results, differences in testing accuracy, high equipment costs, and limited access to advanced diagnostic infrastructure may restrict adoption in certain healthcare settings.

Go Deeper! Ask Prism AI

about the Global Urinary Tract Infection Testing Market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Key Market Segments

By type, cystitis accounted for the largest revenue share of more than 40.0% in 2025. Cystitis is a common form of urinary tract infection involving inflammation of the bladder, frequently caused by bacterial infection. Its high incidence and recurrence, particularly among women, contribute to demand for diagnostic testing. The pyelonephritis segment is expected to register the fastest growth during the forecast period as healthcare providers focus on identifying kidney infections that may require prompt medical intervention.

By end use, reference laboratories held the largest revenue share of more than 25.0% in 2025. These facilities process large volumes of diagnostic samples and provide specialized testing services to hospitals, clinics, and other healthcare providers. Their established laboratory infrastructure, technical expertise, and ability to conduct advanced diagnostic procedures support segment leadership.

Other important end-use categories include general practitioners, urologists, urogynecologists, hospital laboratories, hospital emergency departments, and urgent care facilities. Urogynecology services are gaining importance as awareness of urinary health and recurrent infections increases.

Regional Market Performance

North America dominated the global urinary tract infection testing market in 2025, accounting for approximately 35.0% of total revenue. The region benefits from advanced diagnostic infrastructure, high healthcare expenditure, growing awareness of infection management, and the presence of established diagnostic companies. The United States represents a major contributor, supported by extensive laboratory networks and demand for advanced testing technologies.

Asia Pacific is expected to register the fastest growth from 2026 to 2033. Rising UTI incidence, expanding healthcare infrastructure, a large patient population, and increasing demand for affordable diagnostic services are supporting regional development. China, India, Japan, South Korea, and Australia represent important markets for UTI testing solutions.

Europe remains a significant market due to established healthcare systems, laboratory testing capabilities, and increasing attention to antimicrobial resistance. Countries such as Germany, the United Kingdom, and France are supporting demand through investments in diagnostic technologies and clinical services.

Latin America and the Middle East and Africa are also creating growth opportunities through improvements in healthcare access, laboratory infrastructure, and awareness of urinary tract infections.

Looking for more specific insights? Customize this report to suite your business needs

Top Industry Players

The competitive landscape includes diagnostic technology providers, laboratory equipment manufacturers, and molecular testing companies. Major industry participants include:

• QIAGEN
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthineers
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.
• bioMérieux SA
• T2 Biosystems, Inc.

Companies are focusing on automated testing platforms, molecular diagnostics, rapid pathogen identification, and antimicrobial resistance detection. Strategic acquisitions, product launches, and partnerships with healthcare providers are also helping market participants strengthen their diagnostic portfolios.

Overall, the urinary tract infection testing market is moving toward faster, more accessible, and more accurate diagnostic solutions. Rising infection prevalence, demand for antimicrobial stewardship, laboratory automation, and the expansion of point-of-care testing are expected to support continued market development through 2033.

U.S. Healthcare Facility Mapping & Intelligence Platform - https://www.grandviewresearch.com/horizon/hospital-database

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.